WO2023048643A2 - A surgical tricuspid valve prosthesis - Google Patents

A surgical tricuspid valve prosthesis Download PDF

Info

Publication number
WO2023048643A2
WO2023048643A2 PCT/SG2022/050678 SG2022050678W WO2023048643A2 WO 2023048643 A2 WO2023048643 A2 WO 2023048643A2 SG 2022050678 W SG2022050678 W SG 2022050678W WO 2023048643 A2 WO2023048643 A2 WO 2023048643A2
Authority
WO
WIPO (PCT)
Prior art keywords
tricuspid valve
valve prosthesis
leaflets
leaflet
cords
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/SG2022/050678
Other languages
English (en)
French (fr)
Other versions
WO2023048643A3 (en
Inventor
Theodoros Kofidis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National University of Singapore
National University Hospital Singapore Pte Ltd
Original Assignee
National University of Singapore
National University Hospital Singapore Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National University of Singapore, National University Hospital Singapore Pte Ltd filed Critical National University of Singapore
Priority to AU2022352477A priority Critical patent/AU2022352477A1/en
Priority to CN202280063663.0A priority patent/CN118076321A/zh
Priority to EP22873292.1A priority patent/EP4419046A4/en
Priority to US18/693,526 priority patent/US20240382303A1/en
Priority to JP2024516835A priority patent/JP2024534426A/ja
Publication of WO2023048643A2 publication Critical patent/WO2023048643A2/en
Publication of WO2023048643A3 publication Critical patent/WO2023048643A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
    • A61F2/2412—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body with soft flexible valve members, e.g. tissue valves shaped like natural valves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
    • A61F2/2442—Annuloplasty rings or inserts for correcting the valve shape; Implants for improving the function of a native heart valve
    • A61F2/2445—Annuloplasty rings in direct contact with the valve annulus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
    • A61F2/2442—Annuloplasty rings or inserts for correcting the valve shape; Implants for improving the function of a native heart valve
    • A61F2/2454—Means for preventing inversion of the valve leaflets, e.g. chordae tendineae prostheses
    • A61F2/2457—Chordae tendineae prostheses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
    • A61F2/2412—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body with soft flexible valve members, e.g. tissue valves shaped like natural valves
    • A61F2/2418—Scaffolds therefor, e.g. support stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body

Definitions

  • the present disclosure relates to a prosthetic heart valve.
  • the present disclosure relates to a tricuspid valve prosthesis for surgical replacement of a tricuspid valve.
  • the tricuspid valve is a valve in the heart that is located between the right atrium (upper chamber) and right ventricle (lower chamber).
  • the tricuspid valve allows blood to flow from the right atrium to the right ventricle and ensures that the blood flows in the correct direction from the right atrium to the right ventricle.
  • the tricuspid valve lies within the right trigone of the fibrous skeleton of the heart and consists of the tricuspid valve annulus, the tricuspid valve leaflets, chordae tendineae, and papillary muscles.
  • the tricuspid valve is generally tri-leaflet, with anterior, septal, and posterior leaflets of unequal sizes. Likewise, there are three papillary muscles: septal/medial papillary muscle, inferior papillary muscle, and anterior papillary muscle. The anterior papillary muscle is the largest and originates from the moderator band as it courses toward the right ventricle free wall. The chordae tendineae connect the papillary muscles to the tricuspid leaflets.
  • the tricuspid valve generally has an area of 7 to 9 cm 2 and is the largest of the four cardiac valves present in the heart.
  • the tricuspid valve orifice is made of the tricuspid valve annulus and measures an average of 11.4 cm in males and 10.8 cm in females.
  • the anterosuperior, inferior, and septal margins correspond to each valvular leaflet.
  • Connective tissue around the orifice of the atrioventricular (AV) valves separates the atria from the ventricles, except at the location of the AV bundle.
  • the normal tricuspid annulus is a saddle-shaped structure with the highest points in an antero-posterior orientation and the lowest points in a medio-lateral orientation. In patients with functional tricuspid regurgitation, the annulus dilates along the right ventricular free wall and becomes more circular and planar.
  • the tricuspid valve has three valve leaflets which are thin and membranous with commissures that appear more like indentations than true commissures. They are each named accordingly for their corresponding positions: anterosuperior, inferior or mural, and septal. In turn, the commissures are named anteroseptal, anteroinferior, and inferior.
  • the anterosuperior leaflet is the largest leaflet. It attaches on the posterolateral aspect of the supraventricular crest and extends from the septal limb to the membranous septum, forming part of the anteroseptal commissure. The posterior leaflet is completely attached to the mural surface, guarding the diaphragmatic surface of the AV junction.
  • the septal leaflet is one of the borders of the Triangle of Koch, an anatomical area within the right atrium, with its location demarcated by the coronary sinus orifice, the tendon of Todaro, and the AV node at the apex.
  • the septal leaflet is a clinical landmark to aid in the localization of this conductive tissue during surgery of the right atrioventricular valve.
  • chordae tendineae are thin strong inelastic fibrous cords that extend from the free edge of the cusps of the tricuspid valve to the apices of the papillary muscles within the right ventricle. They transmit the force of the contracting papillary muscles during ventricular systole to the cusps of the valves to prevent the valves from prolapsing into the atria due to the higher pressures generated in the ventricle.
  • anterior papillary muscles there are three papillary muscles in the RV: anterior, inferior, and medial or septal; where anterior papillary muscle is the largest and others are small muscular tips. Each of these muscles correspond to the valvular leaflets it supports in both size and location.
  • the anterior papillary muscle arises from the right anterolateral ventricular wall (TV), below the anteroinferior commissure of the inferior leaflet, blending with the right end of the septomarginal trabecula (SMT).
  • TV right anterolateral ventricular wall
  • SMT septomarginal trabecula
  • the tricuspid valve behaves like a bicuspid valve, in that the septal leaflet remains fixed between the right and left fibrous trigones and the atrial and ventricular septa, while the anterior and posterior leaflets fan into the RV during diastole, and fan back to seal the valve during systole.
  • the annulus helps in this by dilating and constricting during diastole and systole, respectively.
  • Tricuspid valve disease is rare compared with other types of valve disease.
  • the most common form of tricuspid valve disease is tricuspid stenosis, which means the valve leaflets are stiff and do not open all the way. This makes the valve narrow and restricts the blood flow.
  • Another form of valve disease is tricuspid regurgitation. Patients with this condition have leaflets that do not close all the way, and blood leaks backward across the valve instead of flowing into the ventricle. These conditions cause the heart to pump harder to move blood through the body.
  • Tricuspid valve replacement surgery may be done using traditional open-heart surgery or minimally invasive methods, which involve smaller incisions than those used in open-heart surgery and may include robot- assisted techniques.
  • Existing replacement valves fall into two categories: tissue valves, and mechanical valves.
  • Tissue or biological valves are made from animal tissues and valves, with valve leaflets that are soft and thin.
  • Biological tissue valves eventually need to be replaced as they degenerate over time. Biological valves require short-term use of blood-thinning medicines for about three to six months.
  • a tricuspid valve prosthesis to be transplanted into a heart comprising: two or more leaflets each comprising an annular length and two free edges forming a tip, the two or more leaflets joined together at commissures to create a ring, and configured to coapt with each other; and a connector element connected to the tips of the two or more leaflets.
  • the two or more leaflets may coapt with each other edge-to-edge.
  • the two or more leaflets may coapt with each other surface-to-surface.
  • the connector element may be configured to be attached to a papillary muscle of the heart.
  • the papillary muscle may be the anterior papillary muscle.
  • the connector element may be configured to be attached to a free wall of the right ventricle.
  • the tricuspid valve prosthesis may further comprise two or more sets of cords, each set of cords attached to the connector element at a first end.
  • the tricuspid valve prosthesis may further comprise two or more sets of cords, each set of cords attached to the tip of one of the two or more leaflets at a first end, the two or more sets of cords surrounded by the connector element.
  • the connector element may surround a first end of the two or more sets of cords.
  • the connector element spans the length of the two or more sets of cords.
  • the two or more sets of cords may be configured to be attached to one or more papillary muscles of the heart at a second end.
  • the ring may be bean-shaped or saddle-shaped.
  • the free edges may be shaped along a concave arc of a circle.
  • the two or more leaflets may further comprise a slot that splits a tip of the two or more leaflets, the slot comprising two circular arcs.
  • the two circular arcs may be configured to coapt with each other.
  • a tricuspid valve prosthesis to be transplanted into a heart comprising: two or more leaflets each comprising an annular length and two free edges forming a tip, the two or more leaflets joined together at commissures to create a ring, and configured to coapt with each other; and two or more sets of cords, each set of cords attached to the two or more leaflets at a first end.
  • the two or more sets of cords may be sutured together to form a cap, the cap configured to be attached to a papillary muscle of the heart.
  • the papillary muscle is the anterior papillary muscle.
  • the two or more sets of cords may be sutured together to form a cap, the cap configured to be attached to a free wall of the right ventricle.
  • the ring may be bean-shaped or saddle-shaped.
  • the free edges may be shaped along a concave arc of a circle.
  • the two or more leaflets may further comprise a slot that splits a tip of the two or more leaflets, the slot comprising two circular arcs.
  • the two circular arcs may be configured to coapt with each other.
  • the tricuspid valve prosthesis disclosed herein further comprising a stent frame, wherein two or more leaflets may be positioned within the stent frame and wherein the ring may be dimensioned to match perimeter of the stent frame.
  • the stent frame may comprise one or more slots for inserting the two or more leaflets to the stent frame.
  • the stent frame may comprise a plurality of holes for stitching of the two or more leaflets.
  • the stent frame may comprise a medical grade material, for example stainless steel, silicon, plastic, graphene oxide, or mixture thereof.
  • the tricuspid valve prosthesis disclosed herein may further comprise a cuff attached to the stent frame.
  • the cuff may be coated with one or more drugs.
  • FIG. 1 is a schematic illustration of a tricuspid valve prosthesis, in accordance with embodiments of the present disclosure
  • FIG. 2 is a schematic illustration of a tricuspid valve prosthesis implanted in a heart with cords attached to papillary muscles, in accordance with embodiments of the present disclosure
  • FIG. 3A is a schematic illustration of a tricuspid valve prosthesis, which is an alternative embodiment of the tricuspid valve prosthesis of Fig. 1, with cords stitched together, in accordance with embodiments of the present disclosure;
  • FIG. 3B is a schematic illustration of a tricuspid valve prosthesis, which is an alternative embodiment of the tricuspid valve prosthesis of Fig. 1, with cords secured to a connector element, in accordance with embodiments of the present disclosure;
  • FIG. 3C is a schematic illustration of a tricuspid valve prosthesis, which is another alternative embodiment of the tricuspid valve prosthesis of Fig. 1, with a connector element, in accordance with embodiments of the present disclosure;
  • FIGs. 4A and 4B are schematic illustrations of methods of implanting a tricuspid valve prosthesis into a heart, in accordance with embodiments of the present disclosure
  • FIG. 5A is a schematic illustration of a side perspective view of leaflets and ring of a first alternative tricuspid valve prosthesis
  • Fig. 5B is a schematic illustration of a bottom view of leaflets of a first alternative tricuspid valve prosthesis, in accordance with embodiments of the present disclosure
  • FIG. 5C is a schematic illustration of a leaflet and cord of first alternative tricuspid valve prosthesis, in accordance with embodiments of the present disclosure
  • Fig. 5D is a schematic illustration of a top view of results of a finite element method (FEM) analysis of leaflets of first alternative tricuspid valve prosthesis under external pressure of 23 mmHg
  • Fig. 5E is a schematic illustration of a side view of results of a finite element method (FEM) analysis of leaflets of first alternative tricuspid valve prosthesis under maximum principal stress (MPa), in accordance with embodiments of the present disclosure
  • FIG. 6A is a schematic illustration of a side perspective view of a second alternative tricuspid valve prosthesis, in accordance with embodiments of the present disclosure
  • FIG. 6B is a schematic illustration of second alternative tricuspid valve prosthesis in an open state
  • Fig. 6C is a schematic illustration of second alternative tricuspid valve prosthesis in a closed state, in accordance with embodiments of the present disclosure
  • FIG. 6D is a schematic illustration of an alternative cord connected to a leaflet of second alternative tricuspid valve prosthesis, in accordance with embodiments of the present disclosure
  • FIG. 7A is a schematic illustration of leaflets of a third alternative tricuspid valve prosthesis, in accordance with embodiments of the present disclosure.
  • FIG. 7B is a schematic illustration of a leaflet of third alternative tricuspid valve prosthesis, in accordance with embodiments of the present disclosure.
  • Fig. 7C is a schematic illustration of a top view of results of a finite element method (FEM) analysis of leaflets of third alternative tricuspid valve prosthesis under external pressure of 23 mmHg, in accordance with embodiments of the present disclosure;
  • FEM finite element method
  • FIG. 8 A is a schematic illustration of leaflets of a fourth alternative tricuspid valve prosthesis, in accordance with embodiments of the present disclosure.
  • Fig. 8B is a schematic illustration of a top view of results of a finite element method (FEM) analysis of leaflets of fourth alternative tricuspid valve prosthesis under external pressure of 23 mmHg, in accordance with embodiments of the present disclosure;
  • FEM finite element method
  • FIG. 9A is a schematic illustration of a side perspective view of a fifth alternative tricuspid valve prosthesis designed for a type I tricuspid valve
  • Fig. 9B is a schematic illustration of a top view of leaflets of fifth alternative tricuspid valve prosthesis designed for a type I tricuspid valve, in accordance with embodiments of the present disclosure
  • Fig. 9C is a schematic illustration of leaflets and cords of fifth alternative tricuspid valve prosthesis, in accordance with embodiments of the present disclosure
  • Fig. 9D is a schematic illustration of a top view of results of a finite element method (FEM) analysis of leaflets of fifth alternative tricuspid valve prosthesis under external pressure of 23 mmHg, in accordance with embodiments of the present disclosure;
  • FEM finite element method
  • FIG. 10A is a schematic illustration of a side perspective view of a sixth alternative tricuspid valve prosthesis designed for a type IIIB tricuspid valve
  • Fig. 10B is a schematic illustration of a top view of leaflets of sixth alternative tricuspid valve prosthesis designed for a type IIIB tricuspid valve, in accordance with embodiments of the present disclosure
  • FIG. 10C is a schematic illustration of leaflets and cords of sixth alternative tricuspid valve prosthesis, in accordance with embodiments of the present disclosure
  • Fig. 10D is a schematic illustration of a top view of results of a finite element method (FEM) analysis of leaflets of sixth alternative tricuspid valve prosthesis under external pressure of 23 mmHg, in accordance with embodiments of the present disclosure;
  • FEM finite element method
  • FIG. 11A is a schematic illustration of a side perspective view of a seventh alternative tricuspid valve prosthesis and Fig. 1 IB is a schematic illustration of a top view of leaflets of seventh alternative tricuspid valve prosthesis, in accordance with embodiments of the present disclosure;
  • FIG. 11C is a schematic illustration of leaflets and cords of seventh alternative tricuspid valve prosthesis, in accordance with embodiments of the present disclosure.
  • Fig. 1 ID is a schematic illustration of a top view of results of a finite element method (FEM) analysis of leaflets of seventh alternative tricuspid valve prosthesis under external pressure of 23 mmHg, in accordance with embodiments of the present disclosure.
  • FEM finite element method
  • FIG. 12A is a schematic illustration of a top view of a stent comprised in the tricuspid valve prosthesis, in accordance with some embodiments of the present disclosure
  • Fig. 12B is a schematic illustration of a first side perspective view of the stent comprised in the tricuspid valve prosthesis, in accordance with some embodiments of the present disclosure
  • Fig. 12C is a schematic illustration of a second side perspective view of the stent comprised in the tricuspid valve prosthesis, in accordance with some embodiments of the present disclosure
  • Fig. 12D is a schematic illustration of a third side perspective view of the stent comprised in the tricuspid valve prosthesis, in accordance with some embodiments of the present disclosure.
  • FIG. 13A is a schematic illustration of a side perspective view of the stented tricuspid valve prosthesis, in accordance with some embodiments of the present disclosure
  • FIG. 13B is a schematic illustration of a top view of the stented tricuspid valve prosthesis, in accordance with some embodiments of the present disclosure.
  • FIG. 13C is a schematic illustration of an anterior leaflet for the stented tricuspid valve prosthesis, in accordance with some embodiments of the present disclosure
  • FIG. 13D is a schematic illustration of a posterior leaflet of the stented tricuspid valve prosthesis, in accordance with some embodiments of the present disclosure
  • FIG. 13E is a schematic illustration of a septal leaflet of the stented tricuspid valve prosthesis, in accordance with some embodiments of the present disclosure
  • Fig. 14A is an image of a top view of the stented tricuspid valve prosthesis, in accordance with some embodiments of the present disclosure.
  • Fig. 14B is an image of a side perspective view of the stented tricuspid valve prosthesis, in accordance with some embodiments of the present disclosure.
  • Figs. 15A is an image of a top view of the stented tricuspid valve prosthesis during the valve closing, in accordance with some embodiments of the present disclosure.
  • Figs. 15B is an image of a top view of the stented tricuspid valve prosthesis during the valve opening, in accordance with some embodiments of the present disclosure.
  • the terms “plurality” and “a plurality” as used herein may include, for example, “multiple” or “two or more”.
  • the terms “plurality” or “a plurality” may be used throughout the specification to describe two or more components, devices, elements, units, parameters, or the like.
  • the method embodiments described herein are not constrained to a particular order or sequence. Additionally, some of the described method embodiments or elements thereof can occur or be performed simultaneously, at the same point in time, or concurrently. Unless otherwise indicated, use of the conjunction “or” as used herein is to be understood as inclusive (any or all of the stated options).
  • Fig. 1 is a schematic illustration of a tricuspid valve prosthesis 100, in accordance with embodiments of the present disclosure.
  • Tricuspid valve prosthesis 100 may have features that are similar to a natural human tricuspid valve.
  • Tricuspid valve prosthesis 100 is meant to closely reflect the function of the native tricuspid valve, which moves with the natural distortion of the heart muscle.
  • the tricuspid valve prosthesis 100 includes two or more flexible, membrane-like leaflets 104 connected to each other to form an orifice, annulus, or ring 108 for attachment to a tricuspid valve annulus in the heart to allow blood to flow through in one direction.
  • Ring 108 mimics the native tricuspid valve annulus and may be a flat bean-shaped ring, flat circular ring, or a saddle-shaped ring.
  • ring 108 may be flexible or rigid.
  • ring 108 may be formed with an annular length (not shown) of leaflets 104.
  • ring 108 may be formed from, for example, an elastic annuloplasty ring.
  • ring 108 may be formed by folding or rolling leaflets 104 onto itself towards the outer side of tricuspid valve prosthesis 100.
  • ring 108 may be further strengthened by the addition of strips of suitable material such as biomedical fibres, polymers, or bovine pericardium.
  • Rolling or folding leaflets 104 onto itself towards the outer side of tricuspid valve prosthesis 100 may advantageously assist in avoiding the creation of clots at the inner side of tricuspid valve prosthesis 100, and if clots are to be created, they would only appear on the outer side of tricuspid valve prosthesis 100 at the area of the fold or roll of the ring 108 or ring portion, which poses less risk of damaging the efficient operation of tricuspid valve prosthesis 100.
  • the rolling or folding of leaflets 104 forming ring 108 does not include stitching.
  • the flexible ring 108 may also be termed as “non-stented ring”.
  • leaflets 104 mimic the function of native tricuspid valve leaflets.
  • each leaflet 104 may mimic the function of one or more native tricuspid valve leaflets.
  • two or more leaflets 104 may mimic the function of one native tricuspid valve leaflet.
  • first leaflet and second leaflet mimicking the function of a patient’s native posterior leaflet
  • third leaflet and fourth leaflet mimicking the function of a patient’s native septal leaflet
  • fifth leaflet and sixth leaflet mimicking the function of a patient’s native anterior leaflet
  • first leaflet mimicking the function of a patient’s native septal leaflet and a second leaflet mimicking the function of a patient’s native posterior leaflet and anterior leaflet (see Figs. 8A-8B).
  • leaflets 104 may be customised and adjusted based on the size, shape and morphology type of a patient’s native tricuspid valve and annulus, as well as the position of a patient’s native papillary muscles.
  • leaflets 104 may be customized and designed based on images of the patient’s native tricuspid valve. The images may be obtained through an echocardiography study (or other imaging study). From the imaging study, heart chamber sizes and movements are measured. The detailed dimensions of the patient's tricuspid valve annulus, leaflets and cords are also measured from the acquired images.
  • a three-dimensional echocardiography study can be performed with, for example, a transesophageal echocardiography (TEE) probe or a transthoracic echocardiography (TTE) probe.
  • TTE transthoracic echocardiography
  • Segments of the tricuspid valve can be three- dimensionally and four-dimensionally modelled and measured using software such as eSieValves.TM. (Siemens Medical Solutions USA, Inc., Malvern, Pa.).
  • Relevant measurements can include outer and inner diameters of the annulus, annular areas, intertrigonal and intercommisure distances, lengths along various axes of the anterior, septal, and posterior leaflets, and locations of papillary muscles.
  • a three-dimensional study of a tricuspid valve can be performed with computed tomography (CT) or magnetic resonance imaging (MRI). Segmentation of the tricuspid valve area can be performed using the image analysis software and relevant measurements can be obtained.
  • CT computed tomography
  • MRI magnetic resonance imaging
  • the dimensions of leaflets 104 may be optimized with finite element method (FEM) analysis to look at how leaflets 104 may coapt, deform and perform under external pressure within the heart.
  • FEM finite element method
  • leaflets 104 may be formed from natural material or biocompatible composite material which can resist clotting. In some embodiments, adjacent leaflets 104 may be connected to each other at two ends of the annular length (not shown) to form commissures 112. In some embodiments, leaflets 104 may be made of separate pieces of material and adjacent pairs of leaflets 104 sutured together at commissure 112. In other embodiments, leaflets 104 may be constructed from a single piece of material. In some embodiments, commissures 112 may be labelled with laser or with any other appropriate method to assist with orientating tricuspid valve prosthesis 100 during implantation.
  • leaflets 104 may generally be shaped as a three-sided shape, comprising an annular length (not shown) at a top and two free edges 116 forming a tip 122.
  • free edges 116 may taper towards each other forming tip 122. Free edges 116 may be shaped in the form of concave arcs.
  • free edges 116 of a leaflet 104 may coapt edge-to-edge, whereby free edges 116 of a leaflet may coapt or meet with neighbouring free edges 116 located within the same leaflet or a neighbouring leaflet 104 forming a coaptation edge (not shown) to seal and close tricuspid valve prosthesis 100 (see Figs. 5D, 5E, 7C, 8B, 9D, 10D, and 11D). This differs from a patient’s native tricuspid valve where the leaflets open and close by contacting each other or coapting surface-to-surface.
  • tricuspid valve prosthesis 100 in a closed state, there may be increased coaptation between leaflets 104 such that in addition to free edges 116, leaflets 104 may coapt surface-to-surface with a neighbouring leaflet 104 (see Fig. 6C).
  • leaflets 104 In an open state, free edges 116 of a leaflet 104 do not contact each other.
  • tricuspid valve prosthesis 100 may be biased to a closed position. In other embodiments, tricuspid valve prosthesis 100 may be biased to an open position.
  • the tricuspid valve prosthesis 100 may further comprise cords 120 which mimic the native chordae tendineae of the heart.
  • Each cord 120 may comprise a first end 121 and a second end 123.
  • Each cord 120 may be connected at first end 121 to a tip 122 or a body of leaflet 104.
  • the tip 122 of leaflet 104 is connected to a connector element (such as connector element 132 of Fig. 3B).
  • the connector element 132 may be connected to the tips 122 of all the leaflets 104.
  • the connector element 132 is connected at its distal end to first end 121 of cord 120.
  • cords 120 there may be one or more cords 120 connected to each leaflet 104.
  • first end 121 of cord 120 may split into branches, with each branch connected to leaflet 104 (see Fig. 6D).
  • Each cord 120 may be formed from the same piece of material as leaflet 104 or may be formed from a separate piece of material and then attached to leaflet 104.
  • cords 120 may be connected at second end 123 to one or more papillary muscles of the right ventricle (see Figs. 2 and 4A) or connected to a free wall of the right ventricle (see Fig. 4B).
  • Cords 120 may be connected to the same or different papillary muscle.
  • each of the cords 120 may be connected to one of the three papillary muscles of the right ventricle (see Fig, 2). In other embodiments, cords 120 may all be connected to one papillary muscle of the right ventricle, preferably the anterior papillary muscle which is the strongest papillary muscle of the right ventricle. In other embodiments, second ends 123 of cords 120 may be connected to a free wall of a right ventricle (see Fig. 4B). Cords 120 connecting leaflets 104 to the papillary muscles or free wall of the right ventricle of the heart allow tricuspid valve prosthesis 100 to interact or “cross-talk” with the heart ventricle, thus reducing the risk of heart failure after implantation.
  • any or all components of tricuspid valve prosthesis 100 including ring 108, leaflets 104, cords 120 and connector element 132 (see Figs. 3B and 3C) may be produced with natural materials and can avoid the inclusion of foreign material, such as pledgets.
  • Homograft material and/or composite material including various combinations of homograft, xenograft and/or autograft material, may be used to fabricate the ring 108, leaflets 104, cords 120, and connector element 132 (see Figs. 3B and 3C).
  • the material used to form any component of tricuspid valve prosthesis 100 may include, but is not limited to, human, bovine or porcine pericardium, decellularized bioprosthetic material, polymers including natural and synthetic polymers, woven biodegradable polymers incorporated with cells, and extracellular materials.
  • Biodegradable natural polymers can include, but are not limited to fibrin, collagen, chitosan, gelatin, hyaluronan, and similar materials thereof.
  • a biodegradable synthetic polymer scaffold that can be infiltrated with cells and extracellular matrix materials can include, but is not limited to, poly(L-lactide), polyglycolide, poly(lactic-co-glycolic acid), poly(caprolactone), polyorthoesters, poly(dioxanone), poly(anhydrides), poly(trimethylene carbonate), polyphosphazenes, and similar materials thereof.
  • Flexible rings 108 may be further customized to provide individualized flexibility or rigidity for the patient.
  • any component of the tricuspid valve prosthesis 100 may be fashioned intraoperative ly with autologous pericardium of the patient. In some embodiments, a tricuspid valve prosthesis 100 can be fabricated from the patient's own pericardium.
  • the tricuspid valve prosthesis 100 may be fabricated from xenogeneic materials (e.g., animal tissues, such as existing valves) over which a layer of the patient's own cultured cells is applied by means of tissue engineering.
  • xenogeneic materials e.g., animal tissues, such as existing valves
  • any or all components of tricuspid valve prosthesis 100, including ring 108, leaflets 104, cords 120 and connector element 132 may be made of synthetic or non-biodegradable materials like plastics, silicones, or stainless steel.
  • Tricuspid valve prostheses of the present invention may be fixed by non-glutaraldehy de -based methods, such as dye-mediated photofixation. Tricuspid valve prostheses of the present disclosure may also be fixed by using alternative cross-linking agents, such as epoxy compounds, carbodiimide, diglycidyl, reuterin, genipin, diphenylphosphorylazide, acyl azides, and cyanamide, or by physical methods, such as ultraviolet light and dehydration.
  • alternative cross-linking agents such as epoxy compounds, carbodiimide, diglycidyl, reuterin, genipin, diphenylphosphorylazide, acyl azides, and cyanamide
  • tricuspid valve prosthesis 100 may be produced directly with biological three- dimensional (3D) printing using biological materials.
  • tricuspid valve prosthesis 100, or some components of tricuspid valve prosthesis 100 may be produced using a template or mould constructed by three-dimensional printing, based on the detailed dimensions obtained from three-dimensional imaging performed pre-operatively.
  • FIG. 2 is a schematic illustration of a tricuspid valve prosthesis 100 implanted in a heart 200 with cords 120 attached to papillary muscles 124, in accordance with embodiments of the present disclosure.
  • the tricuspid valve prosthesis 100 is shown implanted at the location of the native tricuspid valve annulus 204 located between the right atrium 208 and the right ventricle 212.
  • Cords 120 of tricuspid valve prosthesis 100 are shown connected to papillary muscles 124.
  • Cords 120, tethering leaflets 104 (not shown) to the papillary muscles 124 of the patient advantageously provide support to the right ventricular wall throughout the cardiac cycle and prevent the leaflets 104 from opening into the right atrium 208.
  • cords 120 may be between 5 and 15 mm in length, and between 1 and 5 mm in width. In some embodiments, the lengths and widths of cords 120 are adjustable and may be determined based on preoperative echo scans and CT scans performed on the patient receiving tricuspid valve prosthesis 100. In some embodiments, the length of cords 120 may be determined by measuring the distance from a native tricuspid valve annulus 204 to the tip of papillary muscles 124.
  • ring 108 may be custom-made following an ultrasound examination of a patient's heart.
  • a three-dimensional echocardiography study may be performed to obtain detailed anatomical measurements and/or render a three-dimensional model of the patient's heart from which a customized tricuspid valve prosthesis can be produced.
  • Leaflets 104 and cords 120 may also be customized based upon ultrasound imaging of the subject's native tricuspid valve and surrounding anatomy.
  • customized tricuspid valve prostheses may also be produced from data obtained by other imaging modalities which provide three-dimensional information, including cardiac CT and cardiac MRI.
  • tricuspid valve prostheses of the present disclosure may be selected, customized or designed to match the patient’s specific anatomy.
  • the native commissure positions may be marked with a double-armed suture.
  • the sutures marking the native commissure positions may be passed through corresponding points on ring 108 of tricuspid valve prosthesis 100 to guide tricuspid valve prosthesis 100 into the heart 200, such that the corresponding points on ring 108 will land on the double-armed suture marked native commissure positions.
  • the corresponding points on tricuspid valve prosthesis 100 maybe commissures 112.
  • the commissural sutures may be secured by tying.
  • Cords 120 may then be secured onto their corresponding papillary muscle(s).
  • cords 120 may be attached to their corresponding papillary muscle(s) prior to orientation of ring 108 of tricuspid valve prosthesis 100.
  • FIG. 3A is a schematic illustration of a tricuspid valve prosthesis 100-1, which is an alternative embodiment of the tricuspid valve prosthesis 100 of Fig. 1, with cords 120 stitched together, in accordance with embodiments of the present disclosure.
  • the embodiment of Fig. 3 A is similar to the embodiment of Fig. 1, with like-numbered terms configured in the same way, except that the cords 120-1 are stitched together length-wise to form a cap 128.
  • Cap 128 may then be stitched and secured to a papillary muscle 124 of a patient, preferably the anterior papillary muscle (see Fig. 4A). In other embodiments, cap 128 may be secured to a free wall 440 of the right ventricle 212 (see Fig.
  • Cap 128 ensures a single vector of pulling when the heart contracts. Cap 128 also advantageously strengthens the connection between leaflets 104-1 and the papillary muscle 124 or the free wall 440 of the right ventricle 212 as cap 128 brings cords 120-1 together to prevent tearing of cords 120-1 when the papillary muscle 124 or free wall 440 of the right ventricle 212 pulls on cords 120-1 during heart contraction. Cap 128 also ensures uniformity during coaptation so that the coaptation of free edges 116-1 of tricuspid valve prothesis 100-1 is not compromised during heart contraction.
  • cords 120-1 may be stitched together length-wise over a portion of cords 120-1 at a first end connected to leaflets 104-1 such that cords 120-1 are free from each other at a second end and may be attached to separate papillary muscles (not shown). The stitching ensures that there is a single vector of pulling when the heart 200 contracts, even though cords 120-1 may be connected to different papillary muscles.
  • cords 120-1 may be between 2 and 10 mm in length and may be stitched lengthwise over a length of between 2 and 10 mm.
  • the lengths and widths of cords 120-1, as well as the length over which cords 120-1 are stitched are adjustable and may be determined by preoperative echo scans and CT scans performed on the patient receiving tricuspid valve prosthesis 100-1.
  • FIG. 3B is a schematic illustration of a tricuspid valve prosthesis 100-2, which is an alternative embodiment ofthe tricuspid valve prosthesis lOO ofFig. 1, with cords 120-2 secured to a connector element 132, in accordance with embodiments of the present disclosure.
  • the embodiment of Fig. 3B is similar to the embodiment of Fig. 1, with like-numbered terms configured in the same way, except that cords 120-2 are secured to a connector element 132 at a first end of cords 120-2 joined to leaflets 104-2, connector element 132 spanning a portion of the length of cords 120-2.
  • connector element 132 may be a piece of material surrounding or wrapped around cords 120-2 and sutured to cords 120-2.
  • Connector element 132 may be shorter than cords 120-2 such that second end of cords 120-2 are free from each other and may be connected to different papillary muscles 124.
  • cords 120-2 may be between 2 and 10 mm in length, while connector element 132 may surround cords 120-2 over a length of between 1 and 5 mm.
  • the lengths of cords 120-2 and the length of cords 120-2 surrounded by connector element 132 are adjustable and may be determined by preoperative echo scans and CT scans performed on the patient receiving tricuspid valve prosthesis 100-2.
  • connector element 132 may be connected at one end to the tips 122-2 of leaflets 104-2 and on the distal end to a first end of the cords 120-2.
  • connector element 132 is connected to the leaflets 104-2 so as to enable sufficient coaptation when the edges of leaflets 104-2 are in contact one with the other.
  • connector element 132 may be sutured to tips 122-2 of leaflets 104-2.
  • connector element 132 is shaped as ahollow tube (not shown).
  • connector element 132 is shaped as a solid tube having an oval or circular cross section allowing for connecting the tips 122-2 of leaflets 104-2 and cords 120-2 thereto with minimal disruption to blood flow through the tricuspid valve prothesis 100-2.
  • connector element 132 length is between 1 and 5 mm.
  • FIG. 3C is a schematic illustration of atricuspid valve prosthesis 100-3, which is another alternative embodiment of the tricuspid valve prosthesis 100 of Fig. 1, with a connector element 132-3, in accordance with embodiments of the present disclosure.
  • the embodiment of Fig. 3C is similar to the embodiment of Fig.
  • cords (not shown) are secured together with a connector element 132-3 spanning the entire length of cords (not shown).
  • Cords (not shown) secured together with connector element 132-3 may then be stitched and secured to the papillary muscle of a patient, preferably the anterior papillary muscle, or a wall of a ventricle of the heart.
  • Connector element 132-3 strengthens the connection between leaflets 104-3 and the papillary muscle or free wall of the right ventricle as connector element 132-3 brings cords 120-3 together to prevent tearing of cords 120-3 when the anterior papillary muscle pulls on cords 120-3 during heart contraction.
  • connector element 132-3 may be connected at one end to the tips 122-3 of leaflets 104-3 and on the other end to a papillary muscle 124 of the patient, preferably the anterior papillary muscle, or a wall of a ventricle of the heart. In some embodiments, connector element 132-3 is sutured to tips 122-3 of leaflets 104-3. In some embodiments, connector element 132-3 is shaped as a hollow tube (not shown).
  • connector element 132-3 is shaped as a solid tube having an oval or circular cross section allowing for connecting the tips of leaflets 104-3 to a papillary muscle or a free wall of the right ventricle thereto with minimal disruption to blood flow through the tricuspid valve prothesis 100-3.
  • Connector element 132-3 ensures that there is a single vector of pulling when the heart contracts.
  • Connector element 132-3 may advantageously ensure uniformity during coaptation so that the coaptation of free edges 116-3 of tricuspid valve prosthesis 100- 3 is not compromised during heart contraction.
  • Figs. 4 A and 4B are schematic illustrations of methods of implanting tricuspid valve prosthesis 100-3 into a heart 200, in accordance with embodiments of the present disclosure.
  • cords 120-3 secured together with connector element 132-3 together as cap 128 in tricuspid valve prosthesis 100-3 may all be connected to the same papillary muscle 124 in the right ventricle (see Fig. 4A).
  • cords 120-3 secured together with connector element 132-3 may be connected to the anterior papillary muscle as it is the strongest papillary muscle.
  • cords 120-3 secured together with connector element 132-3 in tricuspid valve prosthesis 100-3 may be connected to a free wall 440 of right ventricle 212 (see Fig.
  • cords 120-3 secured together with connector element 132-3 in tricuspid valve prosthesis 100-3 may be connected to free wall 440 of right ventricle 212 by passing cords 120-3 secured together with connector element 132-3 through an incision (not shown) in free wall 440 of right ventricle 212 and stitching cords 120-3 secured together with connector element 132-3 to an inner surface 444 of free wall 440 of right ventricle 212 and an outer surface 448 of free wall 440 of right ventricle 212.
  • Figs. 4A and 4B The methods of implanting tricuspid valve prosthesis 100-3 into heart 200 illustrated in Figs. 4A and 4B may similarly be employed to implant tricuspid valve prosthesis 100-1 with cords 120-1 stitched together into cap 128 into heart 200, or tricuspid valve prosthesis 100-3 with connector element 132-3 joined directly to tips 122-3 of leaflets 104-3.
  • Joining cords 120 secured together with connector element 132 or cap 128, or joining connector element 132-3 directly to the papillary muscles 124 or free wall 440 of the right ventricle 212 provides support to the right ventricular wall throughout the cardiac cycle and prevent the leaflets 104 from opening into the right atrium 208. They also allow tricuspid valve prosthesis 100 to interact or “cross-talk” with the heart ventricle, thus advantageously reducing the risk of heart failure after implantation.
  • FIG. 5A is a schematic illustration of a side perspective view of leaflets 504 and ring 508 of a first alternative tricuspid valve prosthesis 500
  • Fig. 5B is a schematic illustration of a bottom view of leaflets 504 of a first alternative tricuspid valve prosthesis 500, in accordance with embodiments of the present disclosure.
  • First alternative tricuspid valve prosthesis 500 may be designed for a patient with a round-shaped annulus and a papillary muscle that is located close to a centre of the round-shaped annulus.
  • first alternative tricuspid valve prosthesis 500 has a ring 508.
  • Ring 508 is circular to fit a round-shaped annulus of a patient.
  • Ring 508 may have a diameter of between 20 and 35 mm to fit within a native tricuspid valve of a patient. Ring 408 may have a diameter corresponding to a native tricuspid valve annulus of a patient obtained through imaging of the patient’s heart.
  • first alternative tricuspid valve prosthesis 500 has leaflets 504 suspended from ring 508, leaflets 504 connected to each other at commissures 512.
  • First alternative tricuspid valve prosthesis 500 may have three leaflets: a first leaflet 504a, a second leaflet 504b, and a third leaflet 504c.
  • First leaflet 504a may mimic a septal leaflet of a native tricuspid valve
  • second leaflet 504b may mimic a posterior leaflet of a native tricuspid valve
  • third leaflet 504c may mimic an anterior leaflet of a native tricuspid valve.
  • First leaflet 504a may be connected to second leaflet 504b at a first commissure 512a
  • second leaflet 504b may be connected to third leaflet 504c at a second commissure 512b
  • third leaflet 504c may be connected to first leaflet 504a at a third commissure 512c.
  • first leaflet 504a, second leaflet 504b, and third leaflet 504c may be identical, with all three leaflets 504 having the same annular length 532. In other embodiments, first leaflet 504a, second leaflet 504b, and third leaflet 504c may be differing, with the three leaflets 504 having the differing annular lengths 532 (see Fig. 5C). In some embodiments, where ring 508 is round and first leaflet 504a, second leaflet 504b and third leaflet 504c are identical, first alternative tricuspid valve prosthesis 500 would be symmetrical and thus first alternative tricuspid valve prosthesis 500 may be orientated in any way during implantation.
  • Fig. 5C is a schematic illustration of a leaflet 504 and cord 520 of first alternative tricuspid valve prosthesis 500, in accordance with embodiments of the present disclosure.
  • Tip 522 of each leaflet 504 may be connected to a first end 521 of a cord 520.
  • all three cords 520 are joined together to a single papillary muscle, and preferably the anterior papillary muscle.
  • a second end 523 of all three cords 520 may be secured together through any of the methods described above, including suturing cords 520 together to form a cap 128, or wrapping a connector element 132-3 around cords 520, and then secured to a single papillary muscle 124 (see Fig.
  • cords 520 may be stitched together or surrounded with a connector element 132 at a first end 521 connected to leaflets 504 and connected to separate papillary muscles 124 at a second end 523.
  • leaflet 504 may have an annular length 532 formed along a convex arc of 120° of a circle with a radius of between 20 and 40 mm.
  • annular length 532 may be 26.2 mm for a valve of size 25 mm, 28.3 mm for a valve of size 27 mm, 30.4 mm for a valve of size 29 mm, 32.4 mm for a valve of size 31 mm, and 34.5 mm for a valve of size 33 mm.
  • Commissure 512 may have a length of between 3 and 10 mm.
  • free edge 516 may be formed along a concave arc of between 20° and 30° of a circle with a radius of between 30 and 60 mm.
  • cords 520 may have a length of between 5 and 15 mm, and a width of between 2 and 8 mm.
  • the dimensions of leaflet 504 may be determined based on the size of the native tricuspid valve of the patient and the vertical distance between the papillary muscle to the annulus (PM height).
  • first alternative tricuspid valve prosthesis 500 for a size 36 mm circular tricuspid valve with PM height of 30 mm or more may have three identical leaflets 504 with annular length 532 formed along an arc of 59.07° of a circle with a radius of 36.51, commissure 512 with a length of 10 mm, free edge 516 formed along an arc of 28° of a circle with radius 50 mm, and cords 520 with length of 8.62 mm and width of 1.46 mm.
  • leaflets 504a, 504b, and 504c may be dimensioned such that tip 522a of leaflet 504a, tip 522b of leaflet 504b and tip 522c of leaflet 504c converge at a point corresponding to a centre of ring 508 (see Fig. 5B).
  • the various dimensions of leaflets 504 may be optimised and determined using finite element method (FEM) analysis to visualise the opening and closing of first alternative tricuspid valve prosthesis 500 under pressure.
  • FEM finite element method
  • Fig. 5D is a schematic illustration of a top view of results of a finite element method (FEM) analysis of leaflets 504 of first alternative tricuspid valve prosthesis 500 under external pressure of 23 mmHg
  • Fig. 5E is a schematic illustration of a side view of results of a finite element method (FEM) analysis of leaflets 504 of first alternative tricuspid valve prosthesis 500 under maximum principal stress (MPa), in accordance with embodiments of the present disclosure.
  • FEM analysis was carried out on leaflets 504 of first alternative tricuspid valve prosthesis 500 to visualise the opening and closing of tricuspid valve prosthesis 500 under pressure and identify areas of stress.
  • tricuspid valve prosthesis 500 closes at an external pressure of between 10 and 30 mmHg, which is the range of normal pulmonary artery pressure. The darker the area on the model, the higher the stress experienced by the area.
  • the material used for FEM analysis may be bovine pericardium with a thickness of 0.28 mm and Young’s modulus of 30M Pa, although other materials with other properties may be used. In some embodiments, thin and young age bovine pericardium with a low Young’s modulus may be used.
  • free edges 516 coapt with each other under pressure to form coaptation edges 536 and seal tricuspid valve prosthesis 500.
  • FIG. 6A is a schematic illustration of a side perspective view of a second alternative tricuspid valve prosthesis 600, in accordance with embodiments of the present disclosure.
  • Fig. 6B is a schematic illustration of second alternative tricuspid valve prosthesis 600 in an open state
  • Fig. 6C is a schematic illustration of second alternative tricuspid valve prosthesis 600 in a closed state, in accordance with embodiments of the present disclosure.
  • Second alternative tricuspid valve prosthesis 600 is similar to first alternative tricuspid valve prosthesis 500 in that it has a circular annulus and comprises three leaflets: a first leaflet 604a, a second leaflet 604b, and a third leaflet 604c.
  • first leaflet 604a may mimic a septal leaflet of a native tricuspid valve
  • second leaflet 604b may mimic a posterior leaflet of a native tricuspid valve
  • third leaflet 604c may mimic an anterior leaflet of a native tricuspid valve.
  • First leaflet 604a may be connected to second leaflet 604b at a first commissure 612a
  • second leaflet 604b may be connected to third leaflet 604c at a second commissure 612b
  • third leaflet 604c may be connected to first leaflet 604a at a third commissure 612c.
  • First leaflet 604a, second leaflet 604b, and third leaflet 604c may be identical, with all three leaflets 604 having the same annular length 632.
  • Annular lengths 632 of second alternative tricuspid valve prosthesis 600 may be sutured together along commissures 612 to form a ring 608 to be sutured onto a valve annulus 602 (see Fig. 6B).
  • annular length 632 may be 26.2 mm for a valve of size 25 mm, 28.3 mm for a valve of size 27 mm, 30.4 mm for a valve of size 29 mm, 32.4 mm for a valve of size 31 mm, and 34.5 mm for a valve of size 33 mm.
  • first leaflet 604a, second leaflet 604b, and third leaflet 604c may be different, with all three leaflets 604 having differing annular lengths 632.
  • second alternative tricuspid valve prosthesis 600 may be designed for surface-to-surface coaptation of leaflets 604 (see Fig. 6C).
  • the only points of contact between leaflets 604a, 604b and 604c are coaptation points 612a, 612b, and 612c, and free edges 616 of leaflets 604a, 604b and 604c do not contact each other.
  • leaflets 604 in a closed state, leaflets 604 coapt with each other at a surface proximate to free edges 616, forming a coaptation surface 614 between leaflets 604.
  • First leaflet 604a may coapt with second leaflet 604b to form coaptation surface 614a
  • second leaflet 604b may coapt with third leaflet 604c to form coaptation surface 614b
  • third leaflet 604c may coapt with first leaflet 604a to form coaptation surface 614c.
  • Such an embodiment has a higher coaptation surface 614 or area than the edge-to-edge coaptation in first alternative tricuspid valve 500.
  • the area of coaptation surface 614 may be adjusted by altering the curvature of free edges 616.
  • tip 622 of each leaflet 604 may be connected to a first end 621 of a cord 620.
  • all three cords 620 are joined together to a single papillary muscle 124, preferably the anterior papillary muscle.
  • a second end 623 of all three cords 620 may be secured together through any of the methods described above, including suturing cords 620 together to form a cap 128, or wrapping a connector element 132- 3 around cords 620, and then secured to a single papillary muscle 124 (see Fig. 4A) or a free wall 440 of the right ventricle 212 (see Fig. 4B).
  • cords 620 may be stitched together or surrounded with a connector element 132 at first end 621 connected to leaflets 604 and connected to separate papillary muscles 124 at a second end 523.
  • Fig. 6D is a schematic illustration of an alternative cord 620-1 connected to leaflet 604 of second alternative tricuspid valve prosthesis 600, in accordance with embodiments of the present disclosure.
  • cord 620-1 may comprise a first end 621-1 and a second end 623-1.
  • first end 621-1 of cord 620-1 may split into two or more branches 625, with each branch 625 connected to leaflet 604.
  • this may advantageously distribute the pressure effect to a different wall of the ventricle of the heart and may help long term durability of second alternative tricuspid valve prosthesis 600 and prevent heart failure.
  • FIG. 7A is a schematic illustration of leaflets of a third alternative tricuspid valve prosthesis 700, in accordance with embodiments of the present disclosure.
  • Third alternative tricuspid valve prosthesis 700 may be designed for a patient with a round-shaped annulus and a papillary muscle 124 that is located close to a centre of the round-shaped annulus.
  • Third alternative tricuspid valve prosthesis 700 is similar to first alternative tricuspid valve prosthesis 500 in that it has a circular annulus and comprises three leaflets: a first leaflet 704a, a second leaflet 704b, and a third leaflet 704c.
  • first leaflet 704a may mimic a septal leaflet of a native tricuspid valve
  • second leaflet 704b may mimic a posterior leaflet of a native tricuspid valve
  • third leaflet 704c may mimic an anterior leaflet of a native tricuspid valve.
  • first leaflet 704a may be connected to second leaflet 704b at a first commissure 712a
  • second leaflet 704b may be connected to third leaflet 704c at a second commissure 712b
  • third leaflet 704c may be connected to first leaflet 704a at a third commissure 712c.
  • First leaflet 704a, second leaflet 704b, and third leaflet 704c may be identical, with all three leaflets 704 having the same annular length 732.
  • annular length 732 may be 26.2 mm for a valve of size 25 mm, 28.3 mm for a valve of size 27 mm, 30.4 mm for a valve of size 29 mm, 32.4 mm for a valve of size 31 mm, and 34.5 mm for a valve of size 33 mm.
  • first leaflet 704a, second leaflet 704b, and third leaflet 704c may be different, with all three leaflets 704 having differing annular lengths 732.
  • leaflets 704 of third alternative tricuspid valve prosthesis 700 may each comprise two free edges 716 shaped in the form of concave arcs: a first free edge 716a, and a second free edge 716b.
  • First free edge 716a and second free edge 716b may have the same dimensions or differing dimensions.
  • first free edge 716a and second free edge 716b may have the same dimensions and be shaped along a concave arc of 120° of a circle with a radius of between 20 and 35 mm.
  • first free edge 716a and second free edge 716b may be located on either side of leaflet 704.
  • FIG. 7B is a schematic illustration of a leaflet 704 of third alternative tricuspid valve prosthesis 700, in accordance with embodiments of the present disclosure.
  • each leaflet 704 of third alternative tricuspid valve prosthesis 700 is adapted to connect to two cords (not shown).
  • Leaflet 704 may be connected to two cords by introducing a slot 740 into leaflet 704 which splits a tip 722 of leaflet 704 into two separate tips 722a and 722b.
  • Slot 740 is shaped in the general shape of a biconvex lens bound by two circular arcs 744a and 744b, with an open vertex that splits tip 722 of leaflet 704.
  • Slot 740 may be adapted such that the circular arcs 744a and 744b of slot 740 coapt under pressure to form coaptation edges 736b (see Fig. 7C).
  • circular arcs 744a and 744b of slot 740 may be shaped along an arc of between 20° and 30° of a circle with a radius of between 30 and 60 mm.
  • tips 722a and 722b may each be connected to a first end of a cord (not shown), the second end of the cords connected to papillary muscles with methods similar to those described in relation to first alternative tricuspid valve prosthesis 500.
  • leaflets 704 may be optimised and determined using finite element method (FEM) analysis to visualise the opening and closing of tricuspid valve prosthesis under pressure.
  • FEM finite element method
  • Third alternative tricuspid valve prosthesis 700 has a larger effective orifice area (EOA) or valve opening area than first alternative tricuspid valve prosthesis 500 due to the addition of slots 740 into leaflet 704, which may advantageously lead to increased hydrodynamic performance.
  • EOA is a critical metric of valve function such that the larger the EOA, the lower the pressure gradient across the valve. A lower or reduced pressure gradient may reduce wear and tear of the valve and increase durability of the valve as well as improved heart recovery. The patient may suffer less heart failure and better performance.
  • Fig. 7C is a schematic illustration of a top view of results of a finite element method (FEM) analysis of leaflets 704 of third alternative tricuspid valve prosthesis 700 under external pressure of 23 mmHg, in accordance with embodiments of the present disclosure .
  • FEM analysis was carried out on leaflets 704 of third alternative tricuspid valve prosthesis 700 to visualise the opening and closing of third alternative tricuspid valve prosthesis 700 under pressure and identify areas of stress. The darker the area on the model, the higher the stress experienced by the area.
  • the material used for FEM analysis may be bovine pericardium with a thickness of 0.28 mm and Young’s modulus of 30 MPa, although other materials with other properties may be used. As illustrated in Fig.
  • free edges 716 coapt with each other under external pressure to form coaptation edges 736a
  • circular arcs 744a and 744b coapt with each other under external pressure to firm coaptation edges 736b to seal third alternative tricuspid valve prosthesis 700.
  • FIG. 8A is a schematic illustration of leaflets of a fourth alternative tricuspid valve prosthesis 800, in accordance with embodiments of the present disclosure.
  • Fourth alternative tricuspid valve prosthesis 800 may be designed for a patient with a papillary muscle that is located closer to the tricuspid valve annulus edge rather than a centre of the annulus.
  • Fourth alternative tricuspid valve prosthesis 800 has a bean-shaped annulus ring which is a closed elongated curved shaped with a concave arc-shaped indentation on a first longitudinal length.
  • Fourth alternative tricuspid valve prosthesis 800 may comprise two leaflets 804 to achieve good valve closing.
  • Fourth alternative tricuspid valve prosthesis 800 may comprise a first leaflet 804a and a second leaflet 804b.
  • first leaflet 804 may mimic the function of a septal leaflet of a native tricuspid valve
  • second leaflet 804b may mimic the function of a posterior leaflet and an anterior leaflet of a native tricuspid valve.
  • First leaflet 804a may be connected to second leaflet 804b at a first commissure 812a and a second commissure 812b.
  • first commissure 812a may correspond with the posteroseptal commissure of a native tricuspid valve
  • second commissure 812b may correspond with the anteroseptal commissure of a native tricuspid valve .
  • first commissure 812a or second commissure 812b may correspond with the anterioposteror commissure of a native tricuspid valve, or any other suitable position may not correspond to a commissure of a native tricuspid valve.
  • the positions of the first commissure 812a and second commissure 812b may be determined based on a location of the papillary muscles of the heart.
  • First commissure 812a and second commissure 812b may have lengths of between 3 and 10 mm.
  • First commissure 812a and second commissure 812b may have the same length, or may have different lengths.
  • annular length 832 of first leaflet 804a may include the concave arc-shaped indentation on the first longitudinal length.
  • First leaflet 804a may have a first annular length of 832a and second leaflet 804b may have a second annular length of 832b.
  • a tricuspid valve prosthesis 800 with a standard size of 25 mm may have a first annular length 832a of 39.0 mm and a second annular length 832b of 45.6 mm.
  • a tricuspid valve prosthesis 800 with a standard size of 27 mm may have a first annular length 832a of 42.2 mm and a second annular length 832b of 49.3 mm.
  • Atricuspid valve prosthesis 800 with a standard size of 29 mm may have a first annular length 832a of 45.3 mm and a second annular length 832b of 52.9 mm.
  • a tricuspid valve prosthesis 800 with a standard size of 31 mm may have a first annular length 832a of 48.4 mm and a second annular length 832b of 56.6 mm.
  • a tricuspid valve prosthesis 800 with a standard size of 33 mm may have a first annular length 832a of 51.5 mm and a second annular length 832b of 60.3 mm.
  • first leaflet 804a may comprise a first free edge 816a and a second free edge 816b.
  • Second leaflet 804a may comprise a third free edge 816c and a fourth free edge 816d.
  • first free edge 816a of first leaflet 804a may coapt with third free edge 816c of second leaflet 804b to form first coaptation edge 836a (see Fig. 8B), while second free edge 816b of first leaflet 804b may coapt with fourth free edge 816d of second leaflet to form coaptation edge 836b (see Fig. 8B).
  • First free edge 816a and third free edge 816c may have corresponding dimensions while second free edge 816b and fourth free edge 816d may have corresponding dimensions.
  • first free edge 816a and third free edge 816c may be formed along an arc of 50° of a circle with radius 21 mm
  • second free edge 816b and fourth free edge 816d may be formed along an arc of 50° of a circle with radius 28 mm.
  • Fig. 8B is a schematic illustration of a top view of results of a finite element method (FEM) analysis of leaflets 804 of fourth alternative tricuspid valve prosthesis 800 under external pressure of 23 mmHg, in accordance with embodiments of the present disclosure .
  • FEM analysis was carried out on leaflets 804 of fourth alternative tricuspid valve prosthesis 800 to visualise the opening and closing of tricuspid valve prosthesis 800 under pressure and identify areas of stress. The darker the area on the model, the higher the stress experienced by the area.
  • the material used for FEM analysis may be bovine pericardium with a thickness of 0.28 mm and Young’s modulus of 30 MPa, although other materials with other properties may be used. As illustrated in Figs.
  • FIG. 9A is a schematic illustration of a side perspective view of a fifth alternative tricuspid valve prosthesis 900 designed for a type I tricuspid valve
  • Fig. 9B is a schematic illustration of a top view of leaflets of fifth alternative tricuspid valve prosthesis 900 designed for a type I tricuspid valve, in accordance with embodiments of the present disclosure. 54% of patients have type I tricuspid valve morphology, which is the most prevalent tricuspid valve morphology.
  • a type I tricuspid valve has three leaflets: a septal leaflet, a posterior leaflet, and an anterior leaflet.
  • the anterior papillary muscle of a type I tricuspid valve is located slightly offset towards the posterior leaflet and anterior leaflet.
  • fifth alternative tricuspid valve prosthesis 900 designed for a type I tricuspid valve has three leaflets 904: a first leaflet 904a mimicking the septal leaflet of a type I native tricuspid valve, a second leaflet 904b mimicking the posterior leaflet of a type I native tricuspid valve, and a third leaflet 904c mimicking the anterior leaflet of a type I native tricuspid valve.
  • First leaflet 904a may be connected to second leaflet 904b at a first commissure 912a
  • second leaflet 904b may be connected to third leaflet 904c at a second commissure 912b
  • third leaflet 904c may be connected to first leaflet 904a at a third commissure 912c.
  • first commissure 912a may correspond with the posteroseptal commissure of a native tricuspid valve
  • second commissure 912b may correspond with the anteroposterior commissure of a native tricuspid valve
  • third commissure 912c may correspond with the anteroseptal commissure of a native tricuspid valve.
  • commissures 912 may be labelled with laser or with any other appropriate method to assist with orientating fifth alternative tricuspid valve prosthesis 900 during implantation
  • FIG. 9C is a schematic illustration of leaflets 904 and cords 920 of fifth alternative tricuspid valve prosthesis 900, in accordance with embodiments of the present disclosure.
  • First leaflet 904a may have a first annular length 932a
  • second leaflet 904b may have a second annular length 932b
  • third leaflet 904c may have an annular length 932c.
  • Annular lengths 932 of each leaflet 904 and positions of commissures 912 may be adjusted or personalised based on measurements taken of a patient’s native tricuspid valve and annulus. Alternatively, annular lengths 932 may be adjusted based on a valve standard size.
  • a valve with standard size 25 mm may have a first annular length 932a of 27.9 mm, a second annular length 932b of 19.4 mm, and a third annular length 932c of 34.5 mm.
  • a valve with standard size 27 mm may have a first annular length 932a of
  • a valve with standard size 29 mm may have a first annular length 932a of 32.4 mm, a second annular length 932b of 22.5 mm, and a third annular length 932c of 40.0 mm.
  • a valve with standard size 31 mm may have a first annular length 932a of 34.4 mm, a second annular length 932b of 24.1 mm, and a third annular length 932c of 42.8 mm.
  • a valve with standard size 33 mm may have a first annular length 932a of 36.8 mm, a second annular length 932b of 25.6 mm, and a third annular length 932c of 45.5 mm.
  • first leaflet 904a may have a first free edge 916a and a second free edge 916b.
  • Second leaflet 904b may have a third free edge 916c and a fourth free edge 916d.
  • Third leaflet 904c may have a fifth free edge 916e and a sixth free edge 916f.
  • first free edge 916a and third free edge 916c have corresponding dimensions
  • fourth free edge 916d and fifth free edge 916e have corresponding dimensions
  • sixth free edge 916f and second free edge 916b have corresponding dimensions such that when fifth alternative tricuspid valve prosthesis 900 is in a closed state, first free edge 916a of first leaflet 904a may coapt with third free edge 916c of second leaflet 904b to form coaptation edge 936a
  • fourth free edge 916d of second leaflet 904b may coapt with fifth free edge 916e of third leaflet 904c to form coaptation edge 936b
  • sixth free edge 916f of third leaflet 604c may coapt with second free edge 916b of first leaflet 904a to form coaptation edge 936c (see Fig.
  • first free edge 916a and third free edge 916c may be formed along a concave arc of between 50° and 70° of a circle with a radius of between 12 and 18 mm.
  • fourth free edge 916d and fifth free edge 916e may be formed along a concave arc of between 50° and 70° of a circle with a radius of between 10 and 15 mm.
  • sixth free edge 916f and second free edge 916b may be formed along a concave arc of between 30° and 50° of a circle with a radius of between 25 and 35 mm.
  • leaflets 904 may be optimised and determined using finite element method (FEM) analysis to visualise the opening and closing of tricuspid valve prosthesis under pressure.
  • FEM finite element method
  • leaflets 904a, 904b and 904c are dimensioned such that the tips of the leaflets converge at a point above a single papillary muscle 124, preferably the anterior papillary muscle.
  • first leaflet 904a may be connected to a first end of a first cord 920a
  • second leaflet 904b may be connected to a first end of a second cord 920b
  • third leaflet 904c may be connected to a first end of a third cord 920c.
  • first cord 920a may have a length of between 5 and 15 mm, and a width of between 2 and 5 mm.
  • second cord 920b may have a length of between 5 and 15 mm, and a width of between 2 and 5 mm.
  • third cord 920c may have a length of between 5 and 15 mm, and a width of between 2 and 5 mm.
  • cords 920a, 920b and 920c have the same lengths and are connected to a single papillary muscle 124, and preferably the anterior papillary muscle, or free wall 440 of right ventricle 212 through any methods disclosed in Figs. 3 A to 3C, 4A and 4B.
  • Cords 920a, 920b and 920c may be sutured together to form a cap or be surrounded by a connector element 924 before suturing to the single papillary muscle or free wall.
  • Fig. 9D is a schematic illustration of a top view of results of a finite element method (FEM) analysis of leaflets 904 of fifth alternative tricuspid valve prosthesis 900 under external pressure of 23 mmHg, in accordance with embodiments of the present disclosure.
  • the material used for FEM analysis may be bovine pericardium with a thickness of 0.28 mm and Young’s modulus of 30 MPa, although other materials with other properties may be used.
  • free edges 916 coapt with each other under external pressure to form coaptation edges 936 and seal fifth alternative tricuspid valve prosthesis 900.
  • FIG. 10A is a schematic illustration of a side perspective view of a sixth alternative tricuspid valve prosthesis 1000 designed for a type IIIB tricuspid valve
  • Fig. 10B is a schematic illustration of a top view of leaflets of sixth alternative tricuspid valve prosthesis 1000 designed for a type IIIB tricuspid valve, in accordance with embodiments of the present disclosure.
  • 32% of patients have type IIIB tricuspid valve morphology, which is the second- most prevalent tricuspid valve morphology.
  • a type IIIB tricuspid valve has four leaflets: a septal leaflet, two posterior leaflets, and an anterior leaflet.
  • sixth alternative tricuspid valve prosthesis 1000 designed for a type IIIB tricuspid valve has three leaflets 1004: a first leaflet 1004a mimicking the septal leaflet of a type IIIB native tricuspid valve, a second leaflet 1004b mimicking the two posterior leaflets of a type IIIB native tricuspid valve, and a third leaflet 1004c mimicking the anterior leaflet of a type IIIB native tricuspid valve.
  • First leaflet 1004a may be connected to second leaflet 1004b at a first commissure 1012a
  • second leaflet 1004b may be connected to third leaflet 1004c at a second commissure 1012b
  • third leaflet 1004c may be connected to first leaflet 1004a at a third commissure 1012c.
  • first commissure 1012a may correspond with the posteroseptal commissure of a native tricuspid valve
  • second commissure 1012b may correspond with the anteroposterior commissure of a native tricuspid valve
  • third commissure 1012c may correspond with the anteroseptal commissure of a native tricuspid valve.
  • commissures 1012 may be labelled with laser or with any other appropriate method to assist with orientating sixth alternative tricuspid valve prosthesis 1000 during implantation
  • FIG. 10C is a schematic illustration of leaflets 1004 and cords 1020 of sixth alternative tricuspid valve prosthesis 1000, in accordance with embodiments of the present disclosure.
  • First leaflet 1004a may have a first annular length 1032a
  • second leaflet 1004b may have a second annular length 1032b
  • third leaflet 1004c may have an annular length 1032c.
  • annular lengths 1032 of each leaflet 1004 and positions of commissures 1012 may be adjusted or personalised based on measurements taken of a patient’s native tricuspid valve and annulus.
  • annular lengths 1032 may be adjusted based on a valve standard size.
  • a valve with standard size 25 mm may have a first annular length 1032a of 27.6 mm, a second annular length 832b of 34.4 mm, and a third annular length 1032c of 18.9 mm.
  • a valve with standard size 27 mm may have a first annular length 1032a of 29.8 mm, a second annular length 1032b of 37. 1 mm, and a third annular length 1032c of 20.4 mm.
  • a valve with standard size 29 mm may have a first annular length 1032a of 32.0 mm, a second annular length 1032b of 39.9 mm, and a third annular length 1032c of 21.9 mm.
  • a valve with standard size 31 mm may have a first annular length 1032a of 34.2 mm, a second annular length 1032b of 42.6 mm, and athird annular length 1032c of 34.2 mm.
  • a valve with standard size 33 mm may have a first annular length 1032a of 36.4 mm, a second annular length 1032b of 45.3 mm, and a third annular length 1032c of 24.9 mm.
  • first leaflet 1004a may have a first free edge 1016a and a second free edge 1016b.
  • second leaflet 1004b may have a third free edge 1016c and a fourth free edge 1016d.
  • third leaflet 1004c may have a fifth free edge 1016e and a sixth free edge 1016f.
  • first free edge 1016a and third free edge 1016c have corresponding dimensions
  • fourth free edge 1016d and fifth free edge 1016e have corresponding dimensions
  • sixth free edge 1016f and second free edge 1016b have corresponding dimensions such that when sixth alternative tricuspid valve prosthesis 1000 is in a closed state, first free edge 1016a of first leaflet 1004a may coapt with third free edge 1016c of second leaflet 1004b to form coaptation edge 1036a
  • fourth free edge 816d of second leaflet 1004b may coapt with fifth free edge 1016e of third leaflet 1004c to form coaptation edge 1036b
  • sixth free edge 1016f of third leaflet 1004c may coapt with second free edge 1016b of first leaflet 1004a to form coaptation edge 1036c (see Fig.
  • first free edge 1016a and third free edge 1016c may be formed along a concave arc of between 30° and 50° of a circle with a radius of between 25 and 30 mm.
  • Fourth free edge 1016d and fifth free edge 1016e may be formed along a concave arc of between 50° and 70° of a circle with a radius of between 10 and 15 mm.
  • Sixth free edge 1016f and second free edge 1016b may be formed along a concave arc of between 50° and 70° of a circle with a radius of between 15 and 25 mm.
  • leaflets 1004 may be optimised and determined using finite element method (FEM) analysis to visualise the opening and closing of tricuspid valve prosthesis under pressure.
  • FEM finite element method
  • leaflets 1004a, 1004b and 1004c are dimensioned such that the tips of the leaflets converge at a point above a single papillary muscle, preferably the anterior papillary muscle.
  • leaflets 1004 may be connected to the single papillary muscle or free wall though a connector element connected to tips of leaflets 1004.
  • first leaflet 1004a may be connected to a first end of a first cord 1020a
  • second leaflet 1004b may be connected to a first end of a second cord 1020b
  • third leaflet 1004c may be connected to a first end of a third cord 1020c.
  • first cord 1020a may have a length of between 5 and 15 mm, and a width of between 2 and 5 mm.
  • Second cord 1020b may have a length of between 5 and 15 mm, and a width of between 2 and 5 mm.
  • Third cord 1020c may have a length of between 5 and 15 mm, and a width of between 2 and 5 mm.
  • cords 1020a, 1020b and 1020c have the same lengths and are connected to a single papillary muscle 124, and preferably the anterior papillary muscle, or free wall 440 of right ventricle 212 through any methods disclosed in Figs. 3 A to 3C, 4A and 4B.
  • Cords 1020a, 1020b and 1020c may be sutured together to form a cap or be surrounded by a connector element 1024 before suturing to the single papillary muscle or free wall.
  • Fig. 10D is a schematic illustration of a top view of results of a finite element method (FEM) analysis of leaflets 1004 of sixth alternative tricuspid valve prosthesis 1000 under external pressure of 23 mmHg, in accordance with embodiments of the present disclosure.
  • the material used for FEM analysis may be bovine pericardium with a thickness of 0.28 mm and Young’s modulus of 30 MPa, although other materials with other properties may be used.
  • free edges 1016 coapt with each other under external pressure to form coaptation edges 1036 and seal sixth alternative tricuspid valve prosthesis 1000.
  • FIG. 11A is a schematic illustration of a side perspective view of a seventh alternative tricuspid valve prosthesis 1100 and Fig. 1 IB is a schematic illustration of atop view of leaflets of seventh alternative tricuspid valve prosthesis 1100, in accordance with embodiments of the present disclosure.
  • Seventh alternative valve prosthesis 1100 is not designed specifically for any native tricuspid valve morphology.
  • Seventh alternative tricuspid valve prosthesis 1100 has three leaflets 1104: a first leaflet 1104a mimicking the septal leaflet of a native tricuspid valve, a second leaflet 1104b mimicking posterior leaflet of a native tricuspid valve, and a third leaflet 1104c mimicking the anterior leaflet of a native tricuspid valve.
  • First leaflet 1104a may be connected to second leaflet 1104b at a first commissure 1112a
  • second leaflet 1104b may be connected to third leaflet 1104c at a second commissure 1112b
  • third leaflet 1104c may be connected to first leaflet 1104a at a third commissure 1112c.
  • first commissure 1112a may correspond with the posteroseptal commissure of a native tricuspid valve
  • second commissure 1112b may correspond with the anteroposterior commissure of a native tricuspid valve
  • third commissure 1112c may correspond with the anteroseptal commissure of a native tricuspid valve.
  • commissures 1112 may be labelled with laser or with any other appropriate method to assist with orientating seventh alternative tricuspid valve prosthesis 1100 during implantation.
  • FIG. 11C is a schematic illustration of leaflets 1104 and cords 1120 of seventh alternative tricuspid valve prosthesis 1100, in accordance with embodiments of the present disclosure.
  • First leaflet 1104a may have a first annular length 1132a
  • second leaflet 1104b may have a second annular length 1132b
  • third leaflet 1104c may have an annular length 1132c.
  • annular lengths 1132 of each leaflet 1104 and positions of commissures 1112 may be adjusted or personalised based on measurements taken of a patient’s native tricuspid valve and annulus.
  • annular lengths 1132 may be adjusted based on a valve standard size.
  • a valve with standard size 25 mm may have a first annular length 1132a of 27.7 mm, a second annular length 832b of 19.7 mm, and a third annular length 1132c of 34.5 mm.
  • a valve with standard size 27 mm may have a first annular length 1132a of 30.0 mm, a second annular length 1132b of 21.3 mm, and a third annular length 1132c of 37.3 mm.
  • a valve with standard size 29 mm may have a first annular length 1132a of 32.2 mm, a second annular length 1132b of 22.8 mm, and a third annular length 1132c of 40.0 mm.
  • a valve with standard size 31 mm may have a first annular length 1132a of 34.4 mm, a second annular length 1132b of 24.4 mm, and a third annular length 1132c of 42.8 mm.
  • a valve with standard size 33 mm may have a first annular length 1132a of 36.6 mm, a second annular length 1132b of 26.0 mm, and a third annular length 1132c of 45.6 mm.
  • first leaflet 1104a may have a first free edge 1116a and a second free edge 1116b.
  • Second leaflet 1104b may have a third free edge 1116c and a fourth free edge 1116d.
  • Third leaflet 1104c may have a fifth free edge 1116e and a sixth free edge 1116f
  • first free edge 1116a and third free edge 1116c have corresponding dimensions
  • fourth free edge 1116d and fifth free edge 1116e have corresponding dimensions
  • sixth free edge 1116f and second free edge 1116b have corresponding dimensions such that when seventh alternative tricuspid valve prosthesis 1100 is in a closed state, first free edge 1116a of first leaflet 1104a may coapt with third free edge 1116c of second leaflet 1104b to form coaptation edge 1136a, fourth free edge 1116d of second leaflet 1104b may coapt with fifth free edge 1116e of third leaflet 1104c to form coaptation edge 1136b, and sixth free edge 1116f of third leaflet 1104c may coapt with second free edge 1116b of first leaflet 1104a to form coaptation edge 1136c (see Fig.
  • first free edge 1116a and third free edge 1116c may be formed along a concave arc of between 50° and 70° of a circle with a radius of between 12 and 20 mm.
  • fourth free edge 1116d and fifth free edge 1116e may be formed along a concave arc of between 50° and 70° of a circle with a radius of between 12 and 20 mm.
  • sixth free edge 1116f and second free edge 1116d may be formed along a concave arc of between 50° and 70° of a circle with a radius of between 12 and 18 mm.
  • leaflets 1104 may be optimised and determined using finite element method (FEM) analysis to visualise the opening and closing of tricuspid valve prosthesis under pressure.
  • FEM finite element method
  • leaflets 1104a, 1104b and 1104c are dimensioned such that the tips of the leaflets converge at a point corresponding to a centre of the native tricuspid valve annulus.
  • first leaflet 1104a may be connected to a first end of a first cord 1120a
  • second leaflet 1104b may be connected to a first end of a second cord 1120b
  • third leaflet 1104c may be connected to a first end of a third cord 1120c.
  • first end of cords 1120a, 1120b, and 1120c connected together either through suturing or with a connector element 1124 and second end of cords 1120a, 1120b, and 1120c are free and connected to different papillary muscles.
  • first cord 1120a may be connected to the septal papillary muscle
  • second end of second cord 1120b may be connected to a posterior papillary muscle
  • second end of third cord 1120c may be connected to an anterior papillary muscle.
  • cords 1120a, 1120b, and 1120c may have differing lengths and thickness from each other as they are connected to different papillary muscles which would have different distances from the tips of leaflets 1104a, 1104b and 1100c.
  • first cord 1120a may have a length ofbetween 5 and 15 mm, and a width of between 2 and 5 mm.
  • Second cord 1120b may have a length of between 5 and 15 mm, and a width of between 2 and 5 mm.
  • Third cord 1120c may have a length ofbetween 5 and 15 mm, and a width ofbetween 2 and 5 mm.
  • Fig. 1 ID is a schematic illustration of a top view of results of a finite element method (FEM) analysis of leaflets 1104 of seventh alternative tricuspid valve prosthesis 1100 under external pressure of 23 mmHg, in accordance with embodiments of the present disclosure.
  • the material used for FEM analysis may be bovine pericardium with a thickness of 0.28 mm and Young’s modulus of 30 MPa, although other materials with other properties may be used.
  • free edges 1116 coapt with each other under external pressure to form coaptation edges 1136 and seal seventh alternative tricuspid valve prosthesis 1100.
  • the tricuspid valve prosthesis of the present disclosure may comprise a stent frame 1200. It is therefore to be understood that unless specifically stated, when the tricuspid valve prosthesis disclosed herein does not include a stent frame, the tricuspid valve prosthesis is considered as a non-stented tricuspid valve prosthesis such as those described in Figs. 1, and 3A-3C. However, it is to be appreciated that whenever applicable, in addition to the embodiment that will be described below, the various embodiments of the tricuspid valve prosthesis including the first, second, third, fourth, fifth, sixth and seventh alternative tricuspid valve prostheses (refer to Figs.
  • stent 1200 may be included in the tricuspid valve prosthesis.
  • the terms “stent” and “stent frame” may be used interchangeably and they have the same meaning.
  • Stent 1200 may advantageously be used as a support for the tricuspid valve prosthesis.
  • the tricuspid valve prosthesis may be termed as stented tricuspid valve prosthesis.
  • Tricuspid valve prosthesis provided with a stent frame may advantageously allow ease of retrieval of the valve prosthesis.
  • the perimeter of stent frame 1200 may be adapted to mimic the shape of the native tricuspid valve annulus.
  • the perimeter may be a circle or an irregular circle (such as a bean-shaped ring).
  • Fig. 12A is an exemplary embodiment of the perimeter of stent frame 1200 having irregular circular shape that mimics the shape of the native tricuspid valve annulus.
  • Stent 1200 may be made of stainless steel, silicon, plastic, graphene oxide or other suitable materials.
  • stent 1200 may be made of medical grade materials such as those the U.S. Pharmacopeial Convention (USP) Class VI certified or compliant materials or materials complying with ISO 10993.
  • USP U.S. Pharmacopeial Convention
  • a cuff 1205 may be attached to stent 1200 (see Fig. 13B). It is therefore to be understood that cuff 1205 may be dimensioned to match the perimeter of stent 1200.
  • cuff 1205 may be a fabric cuff band 1205 attached to stent 1200 and is advantageously used to strengthen the ring formed by the pericardium and to stitch the valve with annulus muscle (see Figs. 14A and 14B).
  • cuff 1205 may be considered as a strengthening mechanism for the ring.
  • cuff band 1205 may comprise silicon and a radiopaque wire embedded.
  • One or more drugs may be coated on fabric cuff 1205 or wire to prevent or minimize pannus formation, calcification or combination thereof.
  • stent 1200 may be designed according to the location of the papillary muscles. As can be seen from at least Figs. 12B-12D, in some embodiments, stent 1200 may comprise a plurality of holes 1210 for stitching of the pericardium and one or more slots 1230 for the leaflets (not shown) to be inserted to. In some embodiments, when stent 1200 is made of silicon or other materials of similar properties, stent 1200 may be provided without the plurality of holes. Each hole 1210 of the plurality of holes may have a diameter in a range from about 0.5 mm to about 2 mm, preferably of 1 mm. In some embodiments, the diameter of the hole in the plurality of holes may be uniform.
  • each hole of the plurality of holes may have different diameter ranging from about 0.5 mm to about 2 mm. In some embodiments, the placement or configuration of the plurality of holes 1210 may be adjusted accordingly. In an exemplary embodiment, each hole of the plurality of holes may be spaced in similar distance with the neighbouring or adjacent holes.
  • Each slot of the one or more slots 1230 may have a length from about 8 mm to about 16 mm. In some embodiments, when the valve size is of 29 mm, a suitable length of the slot may be 12 mm. Accordingly, the length of slot 1230 may be adjusted depending on the valve size. In some embodiments, stent frame 1200 may have a thickness from about 0.5 mm to about 2 mm, preferably 1 mm.
  • stent 1200 may have a perimeter of about 100.81 mm and a height of about 15 mm. It is to be understood that such parameters including perimeter and height may be adjusted according to the valve size. Hence, generally stent 1200 may have a perimeter in a range from about 80 mm to about 140 mm. In some embodiments, stent 1200 may have a height in a range from about 12 mm to about 25 mm.
  • Figs. 13C-13E illustrate the three leaflets i.e. anterior leaflet 1204c (Fig. 13 C), posterior leaflet 1204b (Fig. 13D), and septal leaflet 1204a (Fig. 13E) of the stented tricuspid valve described in Figs. 13A and 13B, respectively, but prior to mounting these leaflets to stent frame 1200.
  • each of the leaflets may have three-sided shape as previously discussed.
  • the leaflets or pericardium may comprise extended portions (see the greyed area in Figs.
  • FIG. 13C-13D illustrates stented tricuspid valve prosthesis having stent 1200, fabric cuff band 1205, septal leaflet 1204a, posterior leaflet 1204b and anterior leaflet 1204c.
  • the height of each of the leaflets with cords may be in a range from about 30 mm to 55 mm (see Figs. 13C-13E). In some embodiments, the height measured may include the extended portions mentioned above. In some embodiments, for a valve size of 29 mm, the height of each of the leaflets with cords may be about 43 mm.
  • the tricuspid valve prosthesis with a stent frame may be manufactured by shaping the leaflets by cutting out the pericardium (human or bovine pericardium), followed by stitching the shaped leaflets onto the stent to form the tricuspid valve prosthesis having a stent frame.
  • the shaped leaflets having the extended portions Prior to stitching the leaflets, the shaped leaflets having the extended portions can be mounted to the frame by folding the extended portions of the leaflets. The folding may substantially enclose the one or more slots of the stent frame.
  • the folding may also include attaching a cuff to the frame followed by stitching the leaflets.
  • the shaped leaflets may be anterior leaflet, posterior leaflet and septal leaflet.
  • Figs. 15A and 15B illustrate top view of the stented tricuspid valve prosthesis in accordance with embodiments of the present disclosure.
  • the stented tricuspid valve prosthesis may close (Fig. 15A) and open (Fig. 15B).
  • the leaflets may coapt with each other to form coaptation surfaces or coaptation edges and seal the valve prosthesis.
  • such arrangement may minimize leakage during deployment of the tricuspid valve prosthesis described herein.

Landscapes

  • Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Vascular Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Prostheses (AREA)
PCT/SG2022/050678 2021-09-21 2022-09-21 A surgical tricuspid valve prosthesis Ceased WO2023048643A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2022352477A AU2022352477A1 (en) 2021-09-21 2022-09-21 A surgical tricuspid valve prosthesis
CN202280063663.0A CN118076321A (zh) 2021-09-21 2022-09-21 外科三尖瓣假体
EP22873292.1A EP4419046A4 (en) 2021-09-21 2022-09-21 SURGICAL TRICUSPID VALVE PROSTHESIS
US18/693,526 US20240382303A1 (en) 2021-09-21 2022-09-21 A surgical tricuspid valve prosthesis
JP2024516835A JP2024534426A (ja) 2021-09-21 2022-09-21 外科用三尖弁プロテーゼ

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG10202110444X 2021-09-21
SG10202110444X 2021-09-21

Publications (2)

Publication Number Publication Date
WO2023048643A2 true WO2023048643A2 (en) 2023-03-30
WO2023048643A3 WO2023048643A3 (en) 2023-06-22

Family

ID=85721364

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SG2022/050678 Ceased WO2023048643A2 (en) 2021-09-21 2022-09-21 A surgical tricuspid valve prosthesis

Country Status (6)

Country Link
US (1) US20240382303A1 (https=)
EP (1) EP4419046A4 (https=)
JP (1) JP2024534426A (https=)
CN (1) CN118076321A (https=)
AU (1) AU2022352477A1 (https=)
WO (1) WO2023048643A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116687622A (zh) * 2023-06-05 2023-09-05 广东省人民医院 自膨式三尖瓣金属支架、三尖瓣介入瓣膜、植入系统及制作方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960424A (en) * 1988-06-30 1990-10-02 Grooters Ronald K Method of replacing a defective atrio-ventricular valve with a total atrio-ventricular valve bioprosthesis
GB0125925D0 (en) * 2001-10-29 2001-12-19 Univ Glasgow Mitral valve prosthesis
WO2004032796A2 (en) * 2002-10-10 2004-04-22 The Cleveland Clinic Foundation Method and apparatus for replacing a mitral valve with a stentless bioprosthetic valve
US20060195183A1 (en) * 2005-02-18 2006-08-31 The Cleveland Clinic Foundation Apparatus and methods for replacing a cardiac valve
US20190358034A1 (en) * 2017-02-17 2019-11-28 Mitrapex, Inc. Artificial heart valve
SG10201903404QA (en) * 2019-04-16 2020-11-27 Nat Univ Singapore A naturally designed mitral prosthesis

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116687622A (zh) * 2023-06-05 2023-09-05 广东省人民医院 自膨式三尖瓣金属支架、三尖瓣介入瓣膜、植入系统及制作方法
CN116687622B (zh) * 2023-06-05 2024-04-19 广东省人民医院 自膨式三尖瓣金属支架、三尖瓣介入瓣膜、植入系统及制作方法

Also Published As

Publication number Publication date
WO2023048643A3 (en) 2023-06-22
EP4419046A2 (en) 2024-08-28
US20240382303A1 (en) 2024-11-21
EP4419046A4 (en) 2025-10-15
CN118076321A (zh) 2024-05-24
JP2024534426A (ja) 2024-09-20
AU2022352477A1 (en) 2024-04-04

Similar Documents

Publication Publication Date Title
US10709560B2 (en) Naturally designed mitral prosthesis
EP2124825B1 (en) Annuloplasty device for tricuspid valve repair
US9662208B2 (en) Devices and methods for surgical and percutaneous repair of heart valve lesions
US10398546B2 (en) Mitral prosthesis and methods for implantation
CN103249376B (zh) 减少裂开的瓣膜成形环
US6358277B1 (en) Atrio-ventricular valvular device
US7993395B2 (en) Set of annuloplasty devices with varying anterior-posterior ratios and related methods
EP2621408B1 (en) Aortic valve devices
JP2007524460A (ja) 弁輪形成チェーン
US20240382303A1 (en) A surgical tricuspid valve prosthesis
US11517435B2 (en) Ring-based prosthetic cardiac valve
JP7555545B2 (ja) 自然に設計された僧帽弁プロテーゼ
US20220047387A1 (en) Naturally designed mitral prosthesis
US11324592B2 (en) Naturally designed mitral prosthesis

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2024516835

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2022352477

Country of ref document: AU

Ref document number: AU2022352477

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 18693526

Country of ref document: US

Ref document number: 202280063663.0

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2022352477

Country of ref document: AU

Date of ref document: 20220921

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2022873292

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 11202401979Y

Country of ref document: SG

ENP Entry into the national phase

Ref document number: 2022873292

Country of ref document: EP

Effective date: 20240422